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Extracellular vesicles (EVs) play important roles in
intercellular communications via their content
molecules, and mimic, at least in part, the roles that
are played by their originating cells. Consistent with
this notion, an increasing number of reports have
suggested that EVs derived from mesenchymal stem
cells (MSCs), which are therapeutically beneficial to a
wide range of diseases, can serve as drugs to treat
multiple diseases. EVs contain a variety of molecules,
including proteins, microRNAs, and mRNAs, and are
associated with biological processes in a content
molecule-dependent manner. In this article, we review
the latest reports regarding the therapeutic potential
of MSC-EVs by focusing on the underlying molecular
mechanisms of their effects. Specifically, we feature
the effects of MSC-EVs in terms of their content
molecules and of the tissue recovery processes
endowed by these molecules.ings obtained from comprehensive analyses of molecular
components of MSC-EVs; for example, RNA sequencingIntroduction
Interest in extracellular vesicles (EVs), lipid-bilayered
vesicles that are secreted by various types of cells, as
novel carriers for drug delivery systems has increased. In
a broad sense, EVs include all types of vesicles that exist
in the extracellular space. In particular, 50–200 nm EVs,
usually termed exosomes [1] and shedding microvesicles
[2], are the primary focus for many researchers owing to
their biological significance. Thus, in this article, we use
the term “EV” to refer to a 50–200 nm vesicle. Although
the functions of EVs are variable, their functions often
reflect the phenotypes of their originating cells.* Correspondence: tochiya@ncc.go.jp
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(http://creativecommons.org/publicdomain/zeExtracellular vesicles derived from mesenchymal stem
cells (MSC-EVs) have therapeutic benefits against mul-
tiple diseases [3–5]. Mesenchymal stem cells (MSCs)
are stem cells that reside in adult tissues and that assist
in injury recovery. These cells have thus attracted much
attention as a cell source for regenerative medicine.
More recently, increasing numbers of reports have indi-
cated that MSC-EVs show therapeutic effects similar to
those which can be achieved by the originating MSCs
themselves. These findings imply a novel therapeutic
strategy using MSC-EVs as drugs for future regenerative
medicine.
In this article, we review the latest reports regarding
the therapeutic potential of MSC-EVs from the point of
view of their content molecules. To this end, we classify
their content molecules into three groups: proteins,
RNAs, and undefined molecules. The possible molecular
mechanisms underlying MSC-EV-mediated therapeutic
effects are discussed (Fig. 1). We also discuss the further
therapeutic potential of MSC-EVs in terms of the find-
and proteomic analyses of MSC-EVs.Protein-mediated therapeutic effects
Evidence for biological functions of EV proteins was first
provided by immunology studies in the late 1990s
[6–10]. Thereafter, in the 2000s, the involvement of EV
proteins was further described in other fields including
cancer biology [11–13] and neuroscience [14–17]. Evi-
dence for the therapeutic effects of MSC-EV proteins was
not provided until after 2010 (Table 1).
MSC-EVs primarily seem to support the proliferation
and apoptosis avoidance of surviving tissue cells by
modulating intracellular signaling pathways. The earliest
studies found that the therapeutic effect of MSC-derived
paracrine factors on myocardial ischemia/reperfusion
injury (MIR) is largely ascribed to EV fractions [18, 19].is article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 Schematic representation of therapeutic effects mediated by MSC-EVs. MSC-EVs can support the recovery of injured organs, and this supportive
effect is dependent on EV content molecules. In this article, content molecule-dependent therapeutic effects are classified into three categories:
protein-mediated effects, RNA-mediated effects, and undefined molecule-mediated effects (summarized in Tables 1, 2 and 3, respectively).
EV extracellular vesicle, MSC mesenchymal stem cell
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determined specifically, the subsequent study indicated
that this therapeutic effect is mediated by restoring bio-
energetics as evidenced by increased ATP and NADH
levels, reduced oxidative stress via reduced c-JNK phos-
phorylation, and promoted proliferation via PI3K/Akt
pathway activation [20]. Recently, Zhang et al. [21] ele-
gantly demonstrated that MSC-EVs promoted recoveryTable 1 MSC-EV protein-mediated therapeutic effects
Species/MSC
origin
Injured organ/experimental model Responsible
protein
Possib







Heart/mouse model of MIR injury
(ex vivo)
ND Atten






Human/UC Skin/rat skin burn model (in vivo) Wnt4 EV-ca
activi










Aβ amyloid beta, AT adipose tissue, BM bone marrow, ESC embryonic stem cell, EV
reperfusion, MSC mesenchynal stem cell, ND not determined, TGFβ transforming grfrom skin burns by promoting skin cell proliferation.
This proliferative effect was due to EV-Wnt4-mediated
direct promotion of β-catenin nuclear translocation.
EVs allow MSC-derived membrane enzymes with
therapeutic potential to have a unique functional mode.
Our group reported that adipose tissue-derived mesen-
chymal stem cell (ADSC)-EVs contain enzymatically ac-
tive neprilysin (also known as CD10), the rate-limitingle mechanisms for the therapeutic effect Reference
cted to have significant biological effects on cardiac tissue
and repair, but the responsible molecules were not
fically determined
[18]
uated TGFβ signaling and reduced apoptosis [19]
ration of bioenergetics, reduction of oxidative stress and
tion of pro-survival signaling, followed by enhancement of
c function and geometry after MIR injury
[20]
sed ATP and NADH, decreased oxidative stress, increased
horylated Akt and phosphorylated GSK-3β levels, and
ed phosphorylated c-JNK levels
rried Wnt4 promoted β-catenin nuclear translocation and
ty to enhance the proliferation and migration of skin cells
[21]
ediated secretion and transfer of enzymatically active
lysin led to the degradation of intracellular and extracellular
neuroblastoma cell lines
[22]
ition of Th1 cell effector function via EV-CD73-mediated
sine production, which activated the A2A receptor-mediated
sine pathway in the Th1 cells
[23]
extracellular vesicle, GVHD graft-versus-host disease, MIR myocardial ischemia/
owth factor beta, Th1 T-helper type 1, UC umbilical cord
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Coculture experiments strongly suggested that ADSC-
EVs were transferred to amyloid precursor protein-
overexpressing Neuro-2a cells, thereby reducing both
extracellular and intracellular Aβ levels. Currently, we
are investigating the in vivo therapeutic potential of
ADSC-EVs using animal models of Alzheimer’s disease.
Another report also suggested the therapeutic potential
of EV-associated enzymes in graft-versus-host disease
(GVHD) [23]. Bone marrow (BM)-MSC-derived EVs
carry enzymatically functional CD73 (also known as
ecto-5′-nucleotidase), which metabolizes AMP into ad-
enosine, a molecule that contributes to ATP signaling.
Through this signaling, A2AR-expressing T-helper type
1 (Th1) cells are led to apoptosis.
RNA-mediated therapeutic effects
One of the most attractive characteristics of EVs is their
ability to transfer RNAs from one cell to another,
thereby allowing the transferred RNAs to affect the re-
cipient cells. Between 2006 and 2007, a sensational find-
ing demonstrated that EV cargo mRNAs can be
transferred and translated to proteins in recipient cells
[24, 25]. Furthermore, in 2010 EVs were shown to trans-
fer microRNAs (miRNAs) between cells, and the trans-
ferred miRNAs displayed RNA interference (RNAi)
effects in the recipient cells [26–28]. In recent years, EV-
containing RNAs have been shown to be transferred
from MSCs to injured cells and to contribute to tissue
recovery (Table 2).
Although more precise analyses are required, MSC-EV
mRNAs are regarded as therapeutically beneficial inTable 2 MSC-EV RNA-mediated therapeutic effects
Species/
MSC origin
Injured organ/experimental model Responsible
RNA
P

















Human/BM Lung/mouse endotoxin-induced or
LPS-induced acute lung injury (in vivo)
KGF mRNA Im
w
Rat/BM Brain/rat model of middle cerebral artery
occlusion (in vivo)
miR-133b In










Rat/BM Heart/rat regional MIR model (in vivo) miRNA-19a R
o
AKI acute kidney injury, BM bone marrow, EV extracellular vesicle, KGF keratinocyte
miRNA microRNA, MSC mesenchynal stem cell, PTEN phosphatase and tensin homoinjured tissue recovery. The first evidence for the thera-
peutic effects of MSC-EVs was provided for kidney in-
jury. Intriguingly, the therapeutic effects of MSC-EVs
were partly mediated by the packaged mRNAs, which
were suggested to be associated with proliferation, tran-
scription regulation, and immunomodulation [29–31].
Another recent study demonstrated more specifically the
association of the transfer of mRNA with acute lung in-
jury (ALI) recovery [32]. EV-containing keratinocyte
growth factor (KGF) mRNA was transferred from BM-
MSCs to alveolar epithelial type II (ATII) cells and trans-
lated to protein. This elevation of KGF protein in ATII
cells, in concert with the immunomodulatory effect of
MSC-EVs, led to protective effects against ALI.
miRNAs are also proposed to be key molecules that
are responsible for MSC-EV-mediated therapeutic po-
tential. miR-133b, a regulator of tyrosine hydroxylase
production and a dopamine transporter, is the best char-
acterized MSC-EV miRNA with therapeutic effects on
cerebral injury. This miRNA was transferred from BM-
MSCs to injured neurons and then induced neurite out-
growth and promoted neural plasticity [33, 34]. Al-
though several putative targets of miR-133b have been
proposed, more detailed evidence is required to determine
the critical role of MSC-EV miR-133b in the observed
therapeutic effects. miR-22 in BM-MSC-EVs is reported
to protect against ischemic heart disease by reducing car-
diomyocyte apoptosis [35]. This anti-apoptotic effect of
miR-22 was suggested to be due to direct targeting of me-
thyl CpG binding protein 2 (mecp2), which is upregulated
in the ischemic heart [36]. In addition, a similar thera-
peutic effect has been reported for miR-19a in BM-MSC-ossible mechanisms for the therapeutic effect Reference
duction of proliferation of surviving intrinsic epithelial cells [29]
duction of survival of tubular epithelial cells via
ti-apoptotic effects
[30]
roliferative and anti-apoptotic effects on surviving
trinsic epithelial cells
[31]
munosuppressive effects partly through KGF elevation,
hich was caused by EV-mediated transfer of KGF mRNA
[32]
duction of neurite outgrowth of neural cells [33]
romotion of functional recovery by increasing neuroblasts
d induction of neurovascular plasticity by increasing vascular
ndothelial cells
[34]
eduction of apoptosis of ischemic cardiomyocytes by directly
rgeting methyl CpG binding protein 2 (Mecp2) via EV cargo
iR-22
[35]
eduction of the expression level of PTEN, a predicted target
f miR-19a, thus activating the Akt and ERK signaling pathways
[37]
growth factor, LPS lipopolysaccharide, MIR myocardial ischemia/reperfusion,
log
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and tensin homolog (PTEN) deleted from chromo-
some 10 [37].
Molecularly undefined mechanisms of
MSC-EV-mediated therapeutic effects
Despite the rapidly increasing number of reports re-
garding the therapeutic effects of MSC-EVs, many
lack detailed investigations identifying the mole-
cule(s) responsible for these effects. As summarized
in Table 3, the therapeutic effects of MSC-EVs in-
clude promotion of proliferation [38–42] and preven-
tion of apoptosis [40, 42, 43] of surviving cells,
modulation of the immune system [38, 41, 44–46],Table 3 MSC-EV-mediated therapeutic effects by undefined respons
Species/MSC origin Injured organ/experimental model
Mouse/BM Kidney/rat model of 5/6 subtotal nephrectomy (in vivo)
Mouse/BM
Human/UC Lung/mouse hypoxic pulmonary hypertension model
(in vivo)
Human/UC Hind limb/rat ischemia model (in vivo)
Rat/BM Brain/rat model of middle cerebral artery occlusion
(in vivo)
Human/UC Kidney/rat cisplatin-induced acute kidney injury model
(in vivo) and in vitro culture of rat tubular epithelial
cells exposed to cisplatin
Human/ESCs Immune system/mouse model of allogeneic skin graft
(in vivo)
Human/ESCs Liver/CCl4-induced mouse liver injury model (in vivo)
Horse/AT Vascular system/ex vivo rat aortic ring and in vitro
scratch assays
Human/BM Lung/SiO2-induced mouse idiopathic pulmonary
fibrosis model (in vivo)
Human/AT Immune system/in vitro culture of stimulated T cells
Rat/BM Brain/rat cortical impact rat model of traumatic brain
injury (in vivo)
Mouse/AT Brain/in vitro culture of neuronal cells exposed to
oxidative stress and ex vivo cerebellar slice cultures
treated with lysophosphatidylcholine
AT adipose tissue, BM bone marrow, ESC embryonic stem cell, EV extracellular vesicsuppression of fibrosis [45, 47], and promotion of
angiogenesis [41, 48, 49].
Because the primary focus of this article is the molecu-
lar mechanisms underlying the therapeutic effects of
MSC-EVs from the point of view of their content mole-
cules, we do not provide a detailed review of those re-
ports that have not elucidated the responsible molecules.
Nevertheless, considering that these reports provide
much insight, we will highlight some of them here. In a
mouse model of allogeneic skin grafts, MSC-EVs con-
tributed to immunosuppression by increasing the num-
ber of CD4+CD25+FoxP3+ regulatory T cells (Tregs)
[46]. This immunosuppressive effect is distinct from that
of MSC-EVs observed in GVHD, where MSC-EVs didible molecules
Possible mechanisms for the therapeutic effect Reference
Fibrosis prevention, interstitial lymphocyte infiltrates, and
absent tubular atrophy
[47]
Suppression of the hypoxic pulmonary influx of
macrophages and the induction of anti-inflammatory and
pro-proliferative mediators
[38]
Promotion of proliferation and tubular structure formation
of endothelial cells in vitro and exemplified in vivo with the
evidence of improvement in the blood flow recovery
[48]
Enhancement of neurite remodeling, neurogenesis and
angiogenesis, which were evidenced by increases in axonal
density and synaptophysin-positive areas, and
doublecortin-positive neuroblast and endothelial cell
numbers
[39]
Decrease in cisplatin-mediated renal oxidative stress and
apoptosis in vivo and increase in renal epithelial cell
proliferation in vitro
[43]
Induction of an attenuated proinflammatory cytokine
response and enhanced anti-inflammatory cytokine
production by monocytes, leading to polarized activation
of CD4+ T cells to CD4+CD25+FoxP3+ regulatory T cells
(Tregs)
[46]
Upregulation of the priming-phase genes during liver
regeneration, which subsequently led to increased
expression of proliferation-related proteins, PCNA
and cyclin D1
[40]
Mechanisms have not been identified [49]
Downregulation of inflammatory response and suppression
of fibrosis as evidenced by decreased collagen deposition
[45]
Inhibitory effect on the differentiation and activation of T
cells and reduced T cell proliferation and IFNγ release in
in vitro stimulated cells
[44]
Increased endothelial cells in the lesion boundary zone and
dentate gyrus, increased numbers of newly formed
immature and mature neurons in the dentate gyrus and
reduced neuroinflammation
[41]
Protection of neurons from apoptotic cell death, promotion
of remyelination and activation of nestin-positive
oligodendroglial precursors
[42]
le, IFNγ interferon gamma, MSC mesenchynal stem cell, UC umbilical cord
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the numbers of Th1 cells and cytotoxic T cells [23].
These two reports suggest that even phenotypically simi-
lar outputs elicited by MSC-EVs are likely to be context
dependent. Thus, clarifying the difference between these
two distinct immunosuppressive effects is intriguing. To
this end, identifying the EV molecule(s) responsible for
these effects more precisely will be important. Another
interesting report suggested the surprising capacity of
EVs as a transportation tool between cells. Islam et al.
[50] reported that MSCs protect against ALI, and these
authors ascribe this therapeutic effect to EV-mediated
intercellular transfer of mitochondria. Before this report,
lung epithelial cells harboring mitochondrial injury were
cocultured with MSCs and were reported to receive
mitochondria from MSCs, thereby recovering their pro-
liferative capacity and lung functions [51]. Islam et al.
[50] claim that this mitochondrial transfer from MSCs
to lung epithelial cells is mediated by EVs; however, no
direct evidence exists showing that the addition of MSC-
EVs to cultured epithelial cells resulted in mitochondrial
transfer. In contrast, another group [32] identified mito-
chondrial genes in MSC-EVs, implying the involvement
of mitochondrial transfer in the therapeutic outcome of
MSC-EVs. Further investigation regarding this possibility
is required. It should also be noted that the stress of
pathophysiological conditions impacts the effects of
MSC-EVs. For example, hypoxia, ischemic conditioning,
or inflammatory conditioning of MSCs is shown to regu-
late protein or miRNA packaging into EVs and to affect
their functional properties [33, 52, 53].
Future perspectives
In the next few years, exploring and understanding more
comprehensively the therapeutic effects of MSC-EVs by
taking advantage of omics data will be important. Specif-
ically, we can expect to be able to predict the beneficial
characteristics of MSC-EVs. An earlier study by Kim
et al. [54] performed proteome analysis of MSC-EVs and
proposed several candidate signaling pathways that were
expected to be activated by MSC-EVs. These predicted
pathways included the Wnt, transforming growth factor
beta (TGFβ), mitogen-activated protein kinase (MAPK),
peroxisome proliferator-activated receptor (PPAR), and
bone morphogenetic protein (BMP) signaling pathways.
Of these pathways, the MAPK and Wnt signaling path-
ways have been confirmed to be activated following
MSC-EV administration [20, 21, 37, 40, 43]. In addition
to pathway prediction, predicting a single EV molecule
as a therapeutic effector will also be beneficial. Although
not predicted as candidate therapeutic effectors, neprily-
sin/CD10 and CD73 were identified in the proteomic
analyses performed by Kim et al. [54]. These two mole-
cules were later proposed to be therapeutically valid, asalready reviewed [22, 23]. Another recent study per-
formed RNA sequencing (RNA-seq) of MSC-EVs [55].
According to this study, EVs were preferentially rich in
mRNAs for transcription factors and angiogenesis-
associated genes. Of these transcription factors, FoxP3
may contribute to immunosuppressive effects because
FoxP3 is a master gene for Treg lineage specification. In
contrast, intriguingly, RNA-seq generated reads for at
least 386 annotated miRNAs but only four of these were
enriched in EVs compared with the original MSCs. This
finding suggests that other mechanisms may underlie
the therapeutic effects of MSC-EVs. Indeed, a more re-
cent RNA-seq study also questioned the presently well-
accepted hypothesis that miRNAs are the primary effec-
tors of the therapeutic potential of MSC-EVs. Baglio
et al. [56] performed RNA-seq to characterize the full
small RNAome of MSC-EVs. Their data indicate that
miRNAs and small nucleolar RNAs (snoRNAs) are sig-
nificantly enriched in cells, while tRNAs and repeats
form a defined pool of RNAs heavily enriched in exo-
somes. These authors also found that tRNA halves,
which are 30–40 nucleotides long and which are pro-
duced by the cleavage of mature cytoplasmic tRNAs, ap-
pear to be massively sorted into MSC-EVs. tRNA halves
have emerged as a novel class of small noncoding RNAs
that might have biological functions [57]; in particular,
5′ tRNA halves are suggested to serve as translation
suppressors [58, 59]. In addition, 5′ tRNA halves are
shown to be present in immune cell-derived EVs [60]
and in body fluids such as blood [61, 62] and semen
[63], suggesting their potential biological significance. In
this regard, the study by Baglio et al. noted the import-
ance of investigating not only miRNAs but also tRNAs
to further explore and understand MSC-EV-mediated
therapeutic effects.
Second, we would like to emphasize the possible onco-
genic risks entailed by MSC-EVs. The pro-proliferative
effects of MSC-EVs on injured cells imply the possibility
that MSC-EVs accelerate cancer progression. At present,
whether MSC-EVs have pro-cancer or anti-cancer effects
remains controversial. Some studies have claimed that
MSC-EVs support cancer progression [64–68], whereas
others have shown the anti-tumorigenic effects of MSC-
EVs [69–74]. Although we do not have a reasonable ex-
planation at present, two reports by Zhu et al. [68, 72]
have provided insight regarding this controversy. The
authors investigated the effects of MSC-EVs on two dif-
ferent types of cancer. While MSC-EVs attenuated the
growth of bladder cancer cells [72], MSC-EVs promoted
the growth and aggressiveness of renal cancer cells [68].
These contradictory observations suggest that MSC-EVs
affect cancer cells in a cancer type-dependent manner.
In addition, considering the notion of cancer recurrence,
apparent anti-cancer effects may reflect the early stage
Katsuda and Ochiya Stem Cell Research & Therapy  (2015) 6:212 Page 6 of 8of cancer cell dormancy. Indeed, some studies have sug-
gested that anti-proliferative effects on cancer cells
should be regarded as induction of cancer cell dor-
mancy, thereby providing a platform for cancer recur-
rence [75, 76]. More comprehensive insight into this
controversial issue is a prerequisite for applying MSC-
EVs to clinical settings.
Third, we should account for an issue regarding inter-
individual variability in MSC-EV function. MSCs that
are indistinguishable based on marker characterization
could display strongly different capacities to produce cy-
tokines and respond to inflammatory licensing [77].
Donor age and gender also affect characteristics of hu-
man MSCs, such as surface marker profiles and clono-
genic capacity [78]. At present, there is no report on the
inter-individual variability of MSC-EVs, and thus we
should comprehensively interrogate this issue and ex-
plore criteria for clinical use of MSC-EVs. For this pur-
pose, it will be important to know the relationship
between the molecular signatures of MSC-EVs and their
therapeutic efficacy, and also to know the relationship
between donor MSC characteristics and the functionality
of the EVs secreted by them. It might also be important
to know whether there is any relationship between
donor MSC characteristics and their productivity of EVs.
Such information will help us to predict clinical out-
comes from administration of a patient’s derived MSC-
EVs.
Conclusion
MSC-EVs have beneficial effects on recovery from a var-
iety of tissue injuries. These effects are mediated by
MSC-EV content molecules including proteins and
RNAs, and elucidation of the underlying mechanisms of
these effects is now in progress. In addition, recently
available omics data suggest a possibility to further ex-
plore and understand the key molecular basis of these
beneficial effects of MSC-EVs. For the realization of clin-
ical applications of MSC-EVs, however, we should be
aware of the oncogenic risks that may be associated with
MSC-EVs.
Note
This article is part of a thematic series on Extracellular
vesicles and regenerative medicine edited by Jeffrey Karp,
Kelvin Ng and Armand Keating. Other articles in
this series can be found at http://stemcellres.com/
series/EVRM.
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